Introducing the Archer™ Targeted Sequencing Technology for Gene Fusion Detection
In 2012 in the United States, lung cancer ranked second in the number of new cancer cases and first in the number of cancer-related deaths. Fusions to the ALK, RET, or ROS1 genes have been identified in up to 7% of NSCLCs and in the case of ALK or ROS1 define a distinct subpopulation of lung cancer patients that are highly responsive to ALK kinase inhibitors, like Crozotinib. Because of this profound therapeutic implication, the latest National Comprehensive Cancer Network Clinical Practice Guidelines recommend screening for ALK or ROS1 fusions in all patients with NSCLC.
- Detection of known and novel gene fusions from as little as 10ng input nucleic acid.
- Objective sequence based data compared to subjective FISH analysis.
- Higher sensitivity than PCR based methods with no prior knowledge of fusion partners and breakpoints required.
- Sample and target multiplexing is more efficient than existing PCR and FISH based methods.
- High on-target percentage of novel enrichment chemistry yields random start sites and
improved sequence data quality.
- Easy to use room temperature stable format, minimizing experimental set up time and
reducing pipetting steps.
- Simple and scalable report that summarizes the results and enables a researcher to explore their data.
- Compatible with both Ion Torrent™ and Illumina® sequencing platforms.
Fusion Detection with High Sensitivity
Fusions are complex molecular rearrangements with significant diversity at the molecular level. The combination of next generation sequencing (NGS) and the Archer targeted sequencing method provides the most sensitive method for detecting gene fusions. Any fusion partner and all breakpoints will be detected when assaying a given gene or oncogene. As an example, the image below shows the diversity associated with KMT2A fusions in MLL.
The Archer product line features a process, Anchored Multiplex PCR (AMP), which simultaneously isolates RNA or DNA sequences of interest and prepares these molecules for next-generation sequencing. First, a DNA adapter is ligated to appropriately sized DNA or cDNA. Second, a set of gene- or target-specific DNA primers is used in conjunction with a universal primer complementary to the adapter to enrich the target sequences by the Polymerase Chain Reaction (PCR). Finally, a second set of gene- or target-specific DNA primers are used in conjunction with the universal primer to further enrich the target sequences by nested-PCR. The enriched library is sequenced and the data analyzed by the proprietary Archer analysis package to generate a final report.
Rapid, Low Cost Targeted Sequencing
Archer products include room temperature stable reagents that minimize reaction set up time and pipetting steps, enabling rapid and reliable sample preparation. The workflow is sequencing platform agnostic and readily multiplexed to reduce assay cost, and culminates with a simple report of actionable re-arrangements with the ability to deep dive to the single nucleotide level.
Note: The information about this product is preliminary. The product is under development, and not commercially available in the U.S., and its future availability cannot be ensured.[note note_color=”#ffffff” radius=”0″]
Contact us if interested in custom diagnostic solutions for detecting gene fusions. We are looking for partners to develop and commercialize this technology.